2. Academic Validation
  3. Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing

Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing

  • J Med Chem. 2018 Oct 11;61(19):8825-8837. doi: 10.1021/acs.jmedchem.8b01005.
Trung T Nguyen 1,  Derong Ding 1,  William R Wolter 2,  Rocio L Pérez 1,  Matthew M Champion 1,  Kiran V Mahasenan 1,  Dusan Hesek 1,  Mijoon Lee 1,  Valerie A Schroeder 2,  Jeffrey I Jones 1,  Elena Lastochkin 1,  Margaret K Rose 1,  Charles E Peterson 3,  Mark A Suckow 2,  Shahriar Mobashery 1,  Mayland Chang 1
Affiliations

Affiliations

  • 1 Department of Chemistry and Biochemistry , University of Notre Dame , Notre Dame , Indiana 46556 , United States.
  • 2 Freimann Life Sciences Center and Department of Biological Sciences , University of Notre Dame , Notre Dame , Indiana 46556 , United States.
  • 3 Center for Wound Healing , Elkhart General Hospital , Elkhart , Indiana 46514 , United States.
PMID: 30212201 DOI: 10.1021/acs.jmedchem.8b01005
Abstract

Diabetic foot ulcers (DFUs) are a significant health problem. A single existing FDA-approved drug for this ailment, becaplermin, is not standard-of-care. We previously demonstrated that upregulation of active matrix metalloproteinase (MMP)-9 is the reason that the diabetic wound in mice is recalcitrant to healing and that MMP-8 participates in wound repair. In the present study, we validate the target MMP-9 by identifying and quantifying active MMP-8 and MMP-9 in human diabetic wounds using an affinity resin that binds exclusively to the active forms of MMPs coupled with proteomics. Furthermore, we synthesize and evaluate enantiomerically pure ( R)- and ( S)-ND-336, as inhibitors of the detrimental MMP-9, and show that the ( R)-enantiomer has superior efficacy in wound healing over becaplermin. Our results reveal that the mechanisms of pathology and repair are similar in diabetic mice and diabetic humans and that ( R)-ND-336 holds promise for the treatment of DFUs as a first-in-class therapeutic.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z